Loading...
01/11 16:17
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. While there is positive guidance with expected revenue growth and international expansion, challenges such as flat Q3 guidance, increased material costs, and declining authorization rates temper optimism. The Q&A session highlights management's efforts to address advertising and reimbursement issues, but uncertainties remain. The lack of clear guidance on pipeline adds and workforce impacts further adds to the neutral sentiment. Given the absence of market cap data, the overall reaction is likely neutral, with no strong catalysts for significant stock movement in either direction.
Revenue for Q2 2025 $9.7 million, a 28% increase year-over-year, driven by a higher number of revenue units and a higher average selling price (ASP).
MyoPro revenue units delivered 178 units, up 13% year-over-year, with 95 units from authorizations and orders received in Q2.
Average Selling Price (ASP) $54,200, a 14% increase year-over-year, attributed to Medicare Part B patients representing 56% of revenue.
International revenue $1.5 million, representing 15% of total revenue, up 41% year-over-year, primarily from Germany.
Pipeline at quarter end 1,611 patients, a 37% increase year-over-year, with 61% having Medicare Advantage or other commercial insurance.
Pipeline additions in Q2 2025 816 patients, up 49% year-over-year, including 54 patients identified by OMP centers of excellence.
Cost per pipeline add $2,926, an 89% increase year-over-year, due to lower lead quality.
Backlog at quarter end 230 patients, down 19% year-over-year, reflecting higher intra-quarter conversion velocity and reduced Medicare Advantage authorizations.
Gross margin for Q2 2025 62.7%, down from 70.8% year-over-year, due to higher material costs, demo unit builds, and overhead spending.
Operating expenses for Q2 2025 $10.6 million, up 65% year-over-year, driven by higher advertising spending and increased headcount.
Advertising expense $2.2 million, a 162% increase year-over-year, to compensate for lower conversion of leads to pipeline adds.
Operating loss for Q2 2025 $4.6 million, compared to $1.1 million in the prior year quarter.
Net loss for Q2 2025 $4.6 million or $0.11 per share, compared to $1.1 million or $0.03 per share in Q2 2024.
Adjusted EBITDA for Q2 2025 Negative $4 million, compared to negative $1.2 million in Q2 2024.
Accounts receivable as of June 30, 2025 $7.1 million, up from $4.7 million as of March 31, due to payment holds and prepayment audits by DME MACs.
Cash, cash equivalents, and short-term investments as of June 30, 2025 $15.5 million, with a cash burn of $10 million in Q2, including a $4 million drawdown on the credit facility.
MyoPro product line: Continued commitment to market leadership with the MyoPro product line, which has shown proven results.
International revenue: International revenue grew by 41% year-over-year, primarily driven by Germany, contributing $1.5 million or 15% of total revenue.
Medicare Part B coverage: Medicare Part B patients represented 56% of revenue in Q2, with a pipeline of 256 patients at quarter-end.
Medicare Advantage plans: Efforts to increase authorizations from Medicare Advantage plans include doubling ALJ hearings and appealing more denials.
Lead generation and pipeline additions: Achieved record lead generation in June, with 4x as many leads as January. However, pipeline additions were impacted by lead quality and patient qualification criteria.
Cost management: Reduced U.S. workforce by 8%, cut outside services, and limited new hires, saving at least $2 million over the next 12 months.
Advertising strategy: Shifted advertising dollars from social media to television, resulting in better patient engagement and increased pipeline adds.
Revenue growth strategy: Updated revenue growth expectations to 23%-29% for 2025, focusing on lead generation, pipeline conversion, and cost management.
O&P channel expansion: Doubled O&P orders from Q1 to Q2 and expanded training for occupational therapists to increase patient referrals.
Lead Quality Issues: The quality of leads, particularly from Facebook, has declined, leading to inefficiencies in converting leads to pipeline adds. This has increased the cost per pipeline add significantly.
Conversion Challenges: Lower conversion rates from pipeline adds to authorizations are impacting backlog growth and revenue. This is partly due to stricter patient inclusion criteria and delays in patient decision-making processes.
Medicare Advantage Denials: High denial rates from Medicare Advantage plans are forcing the company into lengthy appeals processes, delaying revenue recognition and increasing operational costs.
Increased Operating Costs: Higher advertising expenses and increased headcount have driven up operating costs, contributing to a larger operating loss compared to the previous year.
Regulatory and Audit Delays: Prepayment audits by DME MACs and delays in claim processing have negatively impacted cash flow and days sales outstanding.
Economic Pressures: Higher material costs and increased lease expenses have reduced gross margins, impacting overall profitability.
Workforce Reductions: A headcount reduction of 8% in the U.S. workforce was implemented to cut costs, which could impact operational efficiency and employee morale.
Revenue Growth: The company expects revenue growth of 23% to 29% for the full year 2025, reflecting the number of leads, pipeline adds, and insurance authorizations year-to-date in the direct billing channel.
Third Quarter Revenue: Revenue is expected to be between $9.5 million and $10 million, representing a 3% to 9% year-over-year increase.
Cost Management: The company has implemented cost-saving measures, including a headcount reduction of 8% of the U.S. workforce and cuts in outside services spending, expected to save at least $2 million in operating expenses and capital expenditures over the next 12 months.
Advertising Strategy: Advertising dollars are being redirected from social media to television to improve lead quality and reduce cost per pipeline add. Early indications suggest this shift has increased pipeline adds and improved patient engagement.
Medicare Advantage Plans: The company plans to double the number of administrative law judge (ALJ) hearings in the second half of the year to generate more authorizations and increase Medicare Advantage revenue.
International and O&P Channels: The company expects continued order growth from the O&P channel and international revenue streams, which are diversifying revenue sources.
Medicare Part B Patients: The company is proactively engaging with Medicare Part B patients and their healthcare providers to accelerate the path to MyoPro adoption, with roughly half of the second quarter's filled units representing Medicare Part B patients.
Operational Adjustments: The company plans to make only a few critical hires for the rest of the year and expects to exit 2025 with a significantly lower headcount than initially planned.
The selected topic was not discussed during the call.
The earnings call reveals several concerning factors: declining gross margins, increased operating expenses, and widening losses. While there are strategic plans for revenue growth and cost management, the lack of clear guidance on returning to positive adjusted EBITDA and the impact of debt raise concerns. The Q&A session highlights uncertainties, particularly in the international market and the China partnership. These negatives outweigh the positives, leading to a negative sentiment prediction for the stock price over the next two weeks.
The earnings call presents a mixed picture. While there is positive guidance with expected revenue growth and international expansion, challenges such as flat Q3 guidance, increased material costs, and declining authorization rates temper optimism. The Q&A session highlights management's efforts to address advertising and reimbursement issues, but uncertainties remain. The lack of clear guidance on pipeline adds and workforce impacts further adds to the neutral sentiment. Given the absence of market cap data, the overall reaction is likely neutral, with no strong catalysts for significant stock movement in either direction.
The earnings call presents mixed signals: strong revenue growth and improved gross margins are offset by challenges in Medicare Advantage authorizations and increased operating expenses. Positive factors like international growth and advertising efficiency are countered by uncertainties in pipeline conversion and lack of shareholder return plans. Management's vague responses in the Q&A add to the uncertainty. Despite strong guidance, the absence of a shareholder return plan and ongoing operational challenges suggest a neutral stock price movement in the short term.
The earnings call shows strong financial performance with a 162% revenue increase and improved gross margins. Despite higher expenses, the company achieved operating cash flow breakeven and provided optimistic guidance for 2025. The Q&A section highlights effective advertising adjustments and sustainable improvements. Although there are concerns about pipeline authorization rates and some unclear management responses, the overall sentiment remains positive, especially with the expansion into international markets and a significant increase in Medicare revenue contribution.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
